Zollinger-Ellison syndrome: Presentation, response to therapy, and outcome

Digestive and Liver Disease

Volumn 43, Issue 6, 2011, Pages 439-443

  Wilcox, C Mel ^a   Seay, Toni ^a   Arcury, Justin T ^a   Mohnen, Jean ^a   Hirschowitz, Basil I ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Acid hypersecretion; Gastrinoma; Lansoprazole; Multiple endocrine neoplasia; Zollinger Ellison syndrome

Indexed keywords

CHROMOGRANIN A; CONTRAST MEDIUM; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OCTREOTIDE; PROTON PUMP INHIBITOR; SECRETIN;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ABDOMINAL TUMOR; ADULT; AGED; ARTICLE; CANCER RELAPSE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENUM TUMOR; FEMALE; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRINOMA; GASTROSCOPY; HEARTBURN; HELICOBACTER INFECTION; HEMATEMESIS; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MELENA; MORNING DOSAGE; MORTALITY; NAUSEA; PANCREAS TUMOR; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELAPSE; STOMACH ACID; STOMACH ACID SECRETION; STOMACH BIOPSY; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; ZOLLINGER-ELLISON SYNDROME;

EID: 79955896033     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.11.007     Document Type: Article

References (21)

1. Zollinger R.M., Ellison E.H. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955, 142:709-723.
2. Ellison E.H., Wilson S.D. The Zollinger-Ellison syndrome; re-appraisal and evaluation of 260 registered cases. Ann Surg 1964, 160:512-528.
3. Kaplan E.L., Horvath K., Udekwu A., et al. Gastrinomas: a 42-year-experience. World J Surg 1990, 14:365-375.
4. Soga J., Yakuwa Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hep Bil Pancr Surg 1998, 5:77-85.
5. Imamura M., Komoto I., Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg 2006, 30:1-11.
6. Yu F., Venzon D.J., Serrano J., et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999, 17:615-630.
7. Weber H.C., Venzon D.J., Lin J-T., et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995, 108:1637-1649.
8. Termanini B., Gibril F., Reynolds J.C., et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997, 112:335-347.
9. Norton J.A., Alexander H.R., Fraker D.L., et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001, 234:495-506.
10. Roy P.K., Venzon D.J., Feigenbaum K.M., et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine 2001, 80:189-222.
11. Roy P.K., Venzon D.J., Shojamanesh H., et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 2000, 79:379-411.
12. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999, 341:635-644.
13. Hirschowitz B.I., Simmons J., Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005, 3:39-48.
14. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006, 244:410-419.
15. Sutliff V.E., Doppman J.L., Gibril F., et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997, 15:2420-2431.
16. Plöckinger U., Rindi G., Arnold R., et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004, 80:394-424.
17. Fischer L., Kleeff J., Esposito I., et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008, 95:627-635.
18. Metz D.C., Sostek M.B., Ruszniewski P., Forsmark C.E., Monyak J., Pisegna J.R. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007, 102:2648-2654.
19. Metz D.C., Comer G.M., Soffer E., et al. Three year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006, 23:437-444.
20. Hirschowitz B.I., Fineberg N., Wilcox C.M., et al. Costs and risks in the management of patients with gastric acid hypersecretion. J Clin Gastroenterol 2010, 44:28-33.
21. Freston J.W., Hisada M., Peura D.A., et al. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2009, 29:1249-1260.